Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

Last updated: May 19, 2026
Sponsor: Neumora Therapeutics, Inc.
Overall Status: Completed

Phase

1

Condition

Manic Disorders

Alzheimer's Disease

Williams Syndrome

Treatment

NMRA-323511

Placebo

Clinical Study ID

NCT06546995
NMRA-323511-104
  • Ages 55-90
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly.

Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.

Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment.

Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Part A

  • Healthy participants

  • Age 65 to 80 years

  • Body mass index (BMI) ≥18.0 and ≤32.0 kg/m^2 at the screening and check-in visit

Part B

  • Participants aged 55 to 90 years

  • Diagnosis of probable AD or Alzheimer's clinical syndrome according to the NationalInstitute of Aging-Alzheimer's Association criteria at least 12 months prior toscreening

  • Agitation meets the International Psychogeriatric Association (IPA) consensusdefinition

  • Mini-Mental State Examination (MMSE) score = 5 - 24 (mild to severe dementia) atscreening

Exclusion

Exclusion Criteria:

Part A

  • Participant is actively suicidal

  • Is mentally or legally incapacitated or has significant emotional problems at thetime of the screening visit

  • Diagnosis of epilepsy taking anticonvulsants for seizure control, history ofseizures

Part B

  • Dementia or memory impairment due to a reason other than AD

  • Clinically significant neurologic disorder other than AD

  • Have any clinically significant and uncontrolled medical condition

Note: Other protocol defined inclusion/exclusion criteria may apply

Study Design

Total Participants: 87
Treatment Group(s): 2
Primary Treatment: NMRA-323511
Phase: 1
Study Start date:
July 09, 2024
Estimated Completion Date:
November 19, 2025

Connect with a study center

  • Neumora Investigator Site

    Chandler, Arizona 85286
    United States

    Site Not Available

  • Neumora Investigator Site

    Tempe, Arizona 85283
    United States

    Site Not Available

  • Neumora Investigator Site

    Costa Mesa, California 92626
    United States

    Site Not Available

  • Neumora Investigator Site

    Lomita, California 90717
    United States

    Site Not Available

  • Neumora Investigator Site

    Walnut Creek, California 94596
    United States

    Site Not Available

  • Neumora Investigator Site

    Bradenton, Florida 34205
    United States

    Site Not Available

  • Neumora Investigator Site

    Greenacres City, Florida 33467
    United States

    Site Not Available

  • Neumora Investigator Site

    Hallandale, Florida 33009
    United States

    Site Not Available

  • Neumora Investigator Site

    Hialeah, Florida 33016
    United States

    Site Not Available

  • Neumora Investigator Site

    Miami, Florida 33155
    United States

    Site Not Available

  • Neumora Investigator Site

    Miami Springs, Florida 33166
    United States

    Site Not Available

  • Neumora Investigator Site

    Orlando, Florida 32807
    United States

    Site Not Available

  • Neumora Investigator Site

    Pembroke Pines, Florida 33024
    United States

    Site Not Available

  • Neumora Investigator Site

    Port Orange, Florida 32127
    United States

    Site Not Available

  • Neumora Investigator Site

    Miami 4164138, Florida 4155751 33126
    United States

    Site Not Available

  • Neumora Investigator Site

    Atlanta, Georgia 30318
    United States

    Site Not Available

  • Neumora Investigator Site

    Honolulu, Hawaii 96817
    United States

    Site Not Available

  • Neumora Investigator Site

    Boise, Idaho 83704
    United States

    Site Not Available

  • Neumora Investigator Site

    Belmont, Massachusetts 02478
    United States

    Site Not Available

  • Neumora Investigator Site

    Troy, Michigan 48085
    United States

    Site Not Available

  • Neumora Investigator Site

    Toms River, New Jersey 08755
    United States

    Site Not Available

  • Neumora Investigator Site

    Brooklyn, New York 11229
    United States

    Site Not Available

  • Neumora Investigator Site

    East Syracuse, New York 13057
    United States

    Site Not Available

  • Neumora Investigator Site

    Charlotte, North Carolina 28204
    United States

    Site Not Available

  • Neumora Investigator Site

    Mesquite, Texas 75149
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.